第四批中成药集采或将到来，90个药品面临价格厮杀

Core Insights - The fourth batch of traditional Chinese medicine (TCM) centralized procurement is set to begin, following the successful conclusion of the 11th batch of national drug procurement at the end of October [1][4] - A notification regarding the procurement data for the fourth batch has been circulated, confirming the authenticity of the document, although the final version is still pending official release [4][5] - The procurement will involve 90 drugs across 28 procurement groups, primarily focusing on oral medications, with some injections and external medications included [4][5] Procurement Details - The procurement process will start with data submission from medical institutions by November 21, 2023, indicating a structured timeline for the upcoming procurement [4][5] - The list of drugs includes unique products such as Yindan Xinnao Tong soft capsules and Ginkgo biloba injections, as well as several OTC (over-the-counter) products [4][5][6] - Compared to previous batches, the number of procurement groups has increased, with the fourth batch involving more groups than the first and second batches, but similar to the third batch [5][6] Challenges in TCM Procurement - The complexity of TCM procurement includes difficulties in quality evaluation, pricing negotiations, and competition, which pose significant challenges [5][7] - The unique nature of TCM products, including many that have been recently launched, complicates the procurement process, as new drugs are not typically included in chemical drug procurement [5][6] - The high concentration of unique products in the TCM market leads to challenges in price negotiations, as many products lack substitutes, reducing the incentive for companies to lower prices [6][7] Quality Control Measures - A comprehensive quality evaluation system is proposed to ensure that selected TCM products meet safety and efficacy standards, addressing the lack of clear quality evaluation criteria [8][9] - The procurement process will implement strict quality control measures, including a "one-vote veto" system for products failing quality checks, and a more rigorous monitoring mechanism for selected drugs [8][9] - The ongoing optimization of procurement rules is expected to accelerate market reshuffling, encouraging companies to focus on product quality and efficacy rather than marketing [9]